查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997136

预测遗传学市场：按技术、测试类型、产品类型、应用和最终用户分類的全球市场预测 – 2026-2032 年

Predictive Genetics Market by Technology, Test Type, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预测遗传学市场预计到 2025 年将达到 17.5 亿美元，到 2026 年将成长到 20.9 亿美元，到 2032 年将达到 60.8 亿美元，复合年增长率为 19.39%。

主要市场统计数据
基准年 2025 17.5亿美元
预计年份：2026年 20.9亿美元
预测年份 2032 60.8亿美元
复合年增长率 (%) 19.39%

对预测遗传学进行策略性介绍，有系统地组织技术进步、伦理要求、监管限制和商业化优先事项，以满足相关人员的需求。

预测遗传学融合了基因组学、临床实践和商业性创新。定序、分析流程和生物资讯学的进步已经彻底改变了医疗和生命科学领域相关人员预测疾病风险、指导治疗方法选择以及设计人群筛检计画的方式。因此，从实验室运营商到保险公司和平台提供商，相关人员都必须重新思考他们的策略，以适应从被动诊断向预防和预测性医疗模式加速转变的趋势。

技术民主化、监管演变和综合护理模式的融合如何重塑预测遗传学生态系统和商业策略？

预测遗传学的格局正受到多种因素的共同影响而重塑，这些因素既加速了临床应用的发展，也使商业化进程变得更加复杂。技术的普及化，例如更经济实惠的定序、更先进的检测化学以及基于云端的分析，正在拓展临床应用范围，同时也导致供应商生态系统的碎片化。同时，保险公司和医疗保健系统要求提供强有力的临床效用和成本效益证据，这促使医疗服务提供者建立标准化、检验的工作流程，并收集更可靠的疗效数据。

了解2025年美国关税调整对预测遗传学供应链和价格趋势的影响，以及这些影响如何作用于营运、采购和竞争。

2025年美国关税调整为整个预测遗传学价值链的营运和采购决策带来了新的不确定性。某些试剂和仪器组件进口关税的提高可能会影响检查室和定序中心的成本结构，促使其重新检视筹资策略和库存管理。为此，许多机构正在探索近岸外包、寻找替代供应商以及签订长期合约等方式，以减轻贸易波动的价格影响。

全面的细分洞察，揭示技术、检测类型、应用、最终用户和产品类型如何相互交织，从而定义机会和策略重点。

精细的细分观点能够清楚阐明价值创造的所在，以及哪些路径需要差异化的策略。从技术角度来看，微阵列平台在人群层级检测中仍然至关重要，并细分为比较基因组杂合反应和表达微阵列通讯协定。同时，次世代定序涵盖标靶定序、全EXOME定序和全基因测序，取决于研究的深度和范围。聚合酵素链锁反应(PCR) 技术分为数位 PCR 和即时PCR，用于高灵敏度和快速检测，而传统的桑格定序仍作为确认流程。就检测类型而言，癌症筛检备受关注，其中 BRCA 基因检测、大肠癌筛检和肺癌筛检各自呈现不同的临床和商业性发展轨迹。带因者筛检的范围从扩展检测组到单基因携带者检测，而药物药物基因体学则包括与处方流程紧密结合的 CYP 酶活性检测和药物代谢检测。产前检测分为有创产前检测和非侵入性产前检测，风险评估扩展到心血管风险和神经退化性疾病风险等应用领域，这些领域需要整合纵向资料。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和监管细微差别决定了实施路径、偿还方式和营运重点。

在预测遗传学领域，区域趋势对需求、报销途径和监管预期起着至关重要的作用。在美洲，强大的私人保险市场和活跃的直接面向消费者（DMP ）销售管道正在推动临床导向型检测的快速普及，但保险覆盖政策的差异使得在关键治疗领域建立针对性证据势在必行。同时，在欧洲、中东和非洲，国家管理体制和公共卫生优先事项错综复杂地交织在一起。儘管一些地区正在推动集中监管协调，但各国的报销机制却不尽相同，因此，针对特定区域的卫生经济模型和相关人员的合作对于市场准入和扩张至关重要。

结合技术差异化、服务整合、伙伴关係和证据生成，制定竞争性和企业级策略，以在预测遗传学领域中获取价值。

在预测遗传学领域，竞争优势取决于技术领先地位、服务整合以及透过检验的证据展现临床价值的能力。主要企业各自采用独特的策略。有些企业专注于仪器创新和专有化学技术，以确保耗材收入；而有些企业则专注于软体和解读平台，以确保下游利润并实现多体学整合。同时，检查室网路和定序服务供应商正透过工作流程标准化和扩大地域覆盖范围来扩展业务规模。连接仪器製造商和临床实验室、软体供应商和生物製药公司、咨询服务机构和保险公司的策略伙伴关係和跨产业合作，正日益成为提供端到端解决方案的重要机制。

为行业领导者提供可操作的建议，以协调伙伴关係、证据策略、供应链韧性和数据管治与可扩展的商业化计划。

产业领导者应采取多管齐下、切实可行的策略，在管控风险的同时实现成长。首先，优先发展策略伙伴关係，整合检测和结果解读/咨询服务，以提供更高附加价值、更符合临床工作流程且客户留存率更高的服务。其次，投资于符合支付方要求和区域卫生技术评估（HTA）框架的有针对性的临床证据项目。透过在重点适应症中证明治疗效果的改善和成本的降低，减少准入障碍并支持报销谈判。第三，透过供应商多元化、检验的替代试剂以及选择性近岸外包来增强供应链韧性，从而降低关税和物流中断的影响。

采用透明的混合方法调查方法，结合专家访谈、二手证据整合、细分映射和稳健的检验通讯协定。

本研究采用混合方法，将主要质性研究结果与次要证据和方法论三角验证结合。主要资料来源包括对临床负责人、实验室管理人员、支付方和技术供应商的结构化访谈，以及用于检验新假设的检验访谈。次要分析包括同行评审文献、监管指南、临床实践指南和行业技术概述，以确保概念与当前标准保持一致。资料三角验证技术用于协调不同观点，并检验跨资讯来源的主题结论。

总结了综合解决方案、在地化策略、供应链韧性和实证参与如何决定预测遗传学的成功。

预测遗传学正从一个充满前景的概念走向实际应用，但要最大限度地发挥其潜力，需要在技术、证据生成和相关人员参与之间进行精心协调。本报告贯穿始终的一个主题是：结合高品质检测、严谨解读和以患者为中心的服务的全面解决方案，在临床应用和支付认可方面优于单一解决方案。此外，地理和监管方面的差异要求采取本地化方法，而非统一部署；供应链的发展，例如关税变化，也可能对业务的可行性产生重大影响。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：预测遗传学市场：依技术划分

  • 微阵列
    • 比较基因杂合反应
    • 表现谱微阵列
  • 次世代定序
    • 目标序列
    • 全EXOME定序
    • 全基因组定序
  • 聚合酵素链锁反应
    • 数位PCR
    • 即时PCR
  • 桑格定序

第九章：按测试类型分類的预测遗传学市场

  • 癌症筛检
    • BRCA基因检测
    • 大肠直肠癌筛检
    • 肺癌筛检
  • 携带者筛检
    • 扩展基因带原检测
    • 单基因携带者
  • 药物基因体学
    • CYP 检测
    • 药物代谢试验
  • 产前检查
    • 侵入性产前检查
    • 非侵入性产前检测
  • 风险评估
    • 心血管风险
    • 神经退化性疾病的风险

第十章：预测遗传学市场：依产品类型划分

  • 消耗品
  • 装置
  • 服务
    • 遗传咨询
    • 定序服务
      • NGS服务
      • PCR服务
    • 检查服务
  • 软体

第十一章：预测遗传学市场：按应用领域划分

  • 心血管系统
    • 心臟病
    • 中风
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学
    • 乳癌
    • 结肠癌
    • 肺癌
  • 罕见疾病

第十二章：预测遗传学市场：依最终用户划分

  • 学术研究机构
  • 诊断检测实验室
  • 消费者
  • 医院

第十三章：预测遗传学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：预测遗传学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 预测遗传学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国预测遗传学市场

第十七章：中国预测遗传学市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 23andMe Holding Co.
  • Abbott Laboratories
  • Color Health, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics, Inc.
  • Gene by Gene, Ltd.
  • Genomic Prediction, Inc.
  • Guardant Health, Inc.
  • Helix OpCo, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Labcorp Holdings Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8903005C49A9

The Predictive Genetics Market was valued at USD 1.75 billion in 2025 and is projected to grow to USD 2.09 billion in 2026, with a CAGR of 19.39%, reaching USD 6.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.75 billion
Estimated Year [2026] USD 2.09 billion
Forecast Year [2032] USD 6.08 billion
CAGR (%) 19.39%

A strategic introduction to predictive genetics that frames technological advances, ethical imperatives, regulatory constraints, and commercialization priorities for stakeholders

Predictive genetics stands at the intersection of genomic science, clinical practice, and commercial innovation. Advances in sequencing, analytical pipelines, and bioinformatics have transformed how actors across healthcare and life sciences anticipate disease risk, guide therapeutic choices, and design population-level screening programs. As a result, stakeholders from laboratory operators to payers and platform providers must recalibrate strategy to reflect an accelerating shift from reactive diagnosis to preventive and predictive care models.

The introduction of high-throughput technologies and modular service offerings has lowered barriers to entry while raising expectations for analytical rigor, data governance, and clinical validity. Consequently, decision-makers need actionable intelligence that clarifies technology differentiation, application-specific value propositions, and the evolving regulatory and reimbursement landscape. Moreover, ethical considerations around consent, equity of access, and algorithmic transparency are increasingly central to both public perception and policy responses.

This introduction synthesizes the current environment and sets the stage for deeper sections that analyze transformative shifts, tariff impacts, segmentation dynamics, regional nuances, and company-level strategies. By framing key drivers and constraints, this opening establishes the strategic questions stakeholders must address to translate predictive genetics advances into sustainable clinical and commercial outcomes.

How converging technological democratization, regulatory evolution, and integrated care models are reshaping the predictive genetics ecosystem and commercial playbooks

The landscape of predictive genetics is being reshaped by converging forces that accelerate clinical translation even as they complicate commercialization. Technological democratization-characterized by more affordable sequencing, refined assay chemistries, and cloud-enabled analytics-has expanded the addressable clinical use cases while fragmenting the supplier ecosystem. At the same time, payers and health systems are demanding robust evidence of clinical utility and cost-effectiveness, which is driving providers toward standardized validated workflows and stronger outcome data.

Concurrently, regulatory frameworks are evolving to account for complex genomic outputs, algorithm-driven risk scores, and cross-border data flows. This regulatory maturation increases predictability but also raises the cost of market entry for novel platforms and direct-to-consumer offerings. Ethical debates around equitable access and informed consent remain salient, prompting developers and clinical partners to institutionalize governance protocols and community engagement practices.

Finally, market dynamics are favoring integrated solutions that bundle high-quality assays, interpretation services, and post-test counseling, enabling better end-to-end patient journeys. Strategic collaborations between instrument manufacturers, sequencing service providers, clinical laboratories, and software vendors are becoming a primary mechanism to scale validated services. These transformative shifts underscore the need for adaptive business models, targeted clinical evidence generation, and proactive regulatory and payer engagement to realize the promise of predictive genetics.

Understanding the operational, sourcing, and competitive consequences of United States tariff adjustments in 2025 that influence predictive genetics supply chains and pricing dynamics

Tariff changes in the United States during 2025 have introduced a new variable into operational and procurement decisions across the predictive genetics value chain. Increased import duties on certain reagents and instrumentation components can affect cost structures for laboratories and sequencing centers, prompting a reassessment of sourcing strategies and inventory management. In response, many organizations are evaluating nearshoring opportunities, alternative suppliers, and longer-term contracts to mitigate exposure to trade-driven price volatility.

Import constraints also influence the competitive landscape by advantaging vertically integrated suppliers with domestic manufacturing capabilities while pressuring smaller service labs that rely on imported consumables and specialized instruments. Consequently, providers may prioritize investments in supply chain resilience, such as qualifying multiple vendors, increasing safety stock, or investing in modular platforms that accept a broader range of reagents.

Beyond immediate procurement impacts, tariff-driven cost pressures can alter pricing negotiations with payers and clients, intensify the focus on operational efficiency, and accelerate consolidation among smaller players. Therefore, stakeholders should monitor tariff policy developments closely, quantify exposure across product and service lines, and proactively engage suppliers and customers to communicate potential impacts and mitigation strategies.

Comprehensive segmentation insights that reveal how technology, test type, application, end user, and product type intersect to define opportunity and strategic prioritization

A nuanced segmentation lens clarifies where value is created and which pathways demand differentiated strategies. From a technology perspective, microarray platforms remain relevant for population-level assays and are subdivided into comparative genomic hybridization and expression microarray protocols, while next generation sequencing encompasses targeted sequencing, whole exome sequencing, and whole genome sequencing tailored to varying depth and breadth of inquiry; polymerase chain reaction technologies split into digital PCR and real time PCR for high-sensitivity, rapid assays, and legacy Sanger sequencing persists for confirmatory workflows. When considering test type, cancer screening occupies substantial focus with BRCA testing, colorectal cancer screening, and lung cancer screening representing distinct clinical and commercial trajectories; carrier screening ranges from expanded panels to single gene carrier tests, pharmacogenomics includes CYP testing and drug metabolism testing that align tightly with prescribing workflows, prenatal testing differentiates invasive prenatal testing from non invasive prenatal testing, and risk assessment spans cardiovascular risk and neurodegenerative risk applications that require longitudinal data integration.

Application-based segmentation reveals that predictive genetics serves cardiovascular indications such as heart disease and stroke, infectious disease surveillance and outbreak response, neurological disorders, oncology with subdomains like breast cancer, colorectal cancer, and lung cancer, and rare diseases where diagnostic yield is critical. End users include academic research institutes, diagnostic laboratories, direct-to-consumer channels, and hospitals, each with distinct purchasing cycles, validation requirements, and go-to-market expectations. Product types range across consumables, instruments, services, and software; services warrant special attention as they include genetic counseling, sequencing services and testing services, with sequencing service subdivided into NGS service and PCR service. Taken together, these segmentation layers inform where to prioritize evidence generation, product development, and commercial investment to align technical capabilities with clinical workflows and payer expectations.

Regional dynamics and regulatory nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption pathways, reimbursement, and operational priorities

Regional dynamics play a decisive role in shaping demand, reimbursement pathways, and regulatory expectations across the predictive genetics domain. In the Americas, robust private payer markets and active direct-to-consumer channels drive rapid adoption of clinically oriented assays, yet heterogeneity in coverage policies necessitates targeted evidence generation for key therapeutic areas. Meanwhile, Europe, Middle East & Africa presents a patchwork of national regulatory regimes and public health priorities; centralized regulatory harmonization in some jurisdictions coexists with country-level reimbursement variability, making localized health economic models and stakeholder engagement essential for market entry and scale.

In the Asia-Pacific region, diverse healthcare architectures and substantial public investment in genomic initiatives create both opportunities and operational complexity. Some markets emphasize population-scale screening and national genomics strategies, while others remain nascent with constrained reimbursement. Cross-region comparative analyses highlight that regulatory timelines, data localization requirements, and procurement practices differ materially, so companies must adapt pricing, evidence, and partnership approaches by geography. Finally, regional talent pools, laboratory accreditation standards, and supply chain footprints influence where to site manufacturing, service centers, and research collaborations, reinforcing the importance of geography-specific strategic planning.

Competitive dynamics and company-level strategies that combine technology differentiation, service integration, partnerships, and evidence generation to capture value in predictive genetics

Competitive positioning in predictive genetics is defined by technology leadership, service integration, and the ability to demonstrate clinical value through validated evidence. Key companies are adopting distinct approaches: some focus on instrument innovation and proprietary chemistries to lock in consumable revenue streams, others emphasize software and interpretation platforms to capture downstream margin and enable multi-omic integration, while laboratory networks and sequencing service providers scale by standardizing workflows and expanding geographic reach. Strategic partnerships and cross-sector alliances-linking instrument makers with clinical laboratories, software vendors with biopharma, and counseling services with payers-are increasingly prominent as mechanisms to deliver end-to-end solutions.

Intellectual property and regulatory approvals remain differentiators, particularly for assays tied to companion diagnostics or reimbursement-sensitive indications. Companies investing in patient-centric services, such as integrated genetic counseling and longitudinal outcome tracking, are positioned to meet payer expectations for demonstrated utility. Mergers and acquisitions continue to reconfigure the landscape as larger players acquire niche technologies, interpretation capabilities, or regional laboratory capacity to accelerate market access. Overall, competitive success will hinge on the ability to combine technological differentiation with validated clinical pathways, scalable operations, and robust data governance frameworks.

Actionable and pragmatic recommendations for industry leaders to align partnerships, evidence strategy, supply chain resilience, and data governance with scalable commercialization plans

Industry leaders should adopt a multi-pronged, pragmatic approach to capture growth while managing risk. First, prioritize strategic alliances that integrate assays with interpretation and counseling services, thereby creating higher-value, stickier offerings that align with clinical workflows. Second, invest in targeted clinical evidence programs aligned with payer requirements and local HTA frameworks; demonstrating improved outcomes or cost offsets in priority indications will reduce access barriers and support reimbursement negotiations. Third, reinforce supply chain resilience through supplier diversification, validated alternative reagents, and selective nearshoring to mitigate tariff and logistics disruptions.

Additionally, establishing rigorous data governance and privacy practices will be critical to maintaining trust and meeting evolving regulatory expectations; this includes transparent consent processes, secure analytics environments, and mechanisms for equitable access. Firms should also evaluate hybrid business models that combine direct-to-consumer channels with clinician-mediated pathways to expand reach while maintaining clinical oversight. Lastly, leaders must commit to workforce development and clinical education initiatives to broaden genetics literacy among clinicians and payers, thereby accelerating appropriate test utilization and reducing implementation friction.

Transparent mixed-methods research methodology combining expert interviews, secondary evidence synthesis, segmentation mapping, and robust validation protocols

This research employs a mixed-methods approach that integrates primary qualitative insights with secondary evidence synthesis and methodological triangulation. Primary inputs include structured interviews with clinical leaders, laboratory directors, payers, and technology vendors, supplemented by validation interviews that test emerging hypotheses. Secondary analysis encompasses peer-reviewed literature, regulatory guidance, clinical practice guidelines, and industry technical briefs to ensure conceptual alignment with current standards. Data triangulation methods reconcile divergent viewpoints and validate thematic conclusions across sources.

Analytical techniques include segmentation mapping, technology readiness assessment, regulatory pathway analysis, and scenario-based sensitivity reviews. Quality controls involve source triangulation, respondent validation, and internal peer review to ensure robustness and reduce bias. Limitations of the methodology are acknowledged, including variability in national reimbursement practices and the rapidly evolving regulatory environment; where applicable, findings are contextualized rather than presented as universal prescriptions. Finally, recommendations are grounded in repeatable analytical steps to enable stakeholders to adapt the framework to specific geographies, therapeutic areas, or commercial contexts.

Concluding synthesis of how integrated solutions, tailored regional strategies, supply chain resilience, and evidence-based engagement will determine success in predictive genetics

Predictive genetics is transitioning from promise to practiced utility, but realizing its full potential requires deliberate orchestration across technology, evidence generation, and stakeholder engagement. Throughout this report, a consistent theme emerges: integrated solutions that combine high-quality assays, rigorous interpretation, and patient-centered services outperform point solutions in clinical adoption and payer acceptance. Moreover, geographic and regulatory nuances demand tailored approaches rather than one-size-fits-all rollouts, and supply chain dynamics such as tariff changes can materially affect operational viability.

Looking ahead, success will favor organizations that can demonstrate clinical and economic value, maintain flexible and resilient sourcing strategies, and invest in transparent governance to preserve trust. Strategic partnerships and targeted evidence programs will accelerate uptake, while workforce education and clinician engagement will reduce implementation friction. In sum, the pathway to scaling predictive genetics hinges on aligning technological innovation with real-world clinical workflows, reimbursement realities, and responsible data stewardship.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Predictive Genetics Market, by Technology

  • 8.1. Microarray
    • 8.1.1. Comparative Genomic Hybridization
    • 8.1.2. Expression Microarray
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Polymerase Chain Reaction
    • 8.3.1. Digital PCR
    • 8.3.2. Real Time PCR
  • 8.4. Sanger Sequencing

9. Predictive Genetics Market, by Test Type

  • 9.1. Cancer Screening
    • 9.1.1. BRCA Testing
    • 9.1.2. Colorectal Cancer Screening
    • 9.1.3. Lung Cancer Screening
  • 9.2. Carrier Screening
    • 9.2.1. Expanded Carrier
    • 9.2.2. Single Gene Carrier
  • 9.3. Pharmacogenomics
    • 9.3.1. CYP Testing
    • 9.3.2. Drug Metabolism Testing
  • 9.4. Prenatal Testing
    • 9.4.1. Invasive Prenatal Testing
    • 9.4.2. Non Invasive Prenatal Testing
  • 9.5. Risk Assessment
    • 9.5.1. Cardiovascular Risk
    • 9.5.2. Neurodegenerative Risk

10. Predictive Genetics Market, by Product Type

  • 10.1. Consumables
  • 10.2. Instruments
  • 10.3. Services
    • 10.3.1. Genetic Counseling
    • 10.3.2. Sequencing Service
      • 10.3.2.1. NGS Service
      • 10.3.2.2. PCR Service
    • 10.3.3. Testing Service
  • 10.4. Software

11. Predictive Genetics Market, by Application

  • 11.1. Cardiovascular
    • 11.1.1. Heart Disease
    • 11.1.2. Stroke
  • 11.2. Infectious Diseases
  • 11.3. Neurological Disorders
  • 11.4. Oncology
    • 11.4.1. Breast Cancer
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Lung Cancer
  • 11.5. Rare Diseases

12. Predictive Genetics Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Direct To Consumer
  • 12.4. Hospitals

13. Predictive Genetics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Predictive Genetics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Predictive Genetics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Predictive Genetics Market

17. China Predictive Genetics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 23andMe Holding Co.
  • 18.6. Abbott Laboratories
  • 18.7. Color Health, Inc.
  • 18.8. Danaher Corporation
  • 18.9. Eurofins Scientific SE
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Fulgent Genetics, Inc.
  • 18.12. Gene by Gene, Ltd.
  • 18.13. Genomic Prediction, Inc.
  • 18.14. Guardant Health, Inc.
  • 18.15. Helix OpCo, Inc.
  • 18.16. Illumina, Inc.
  • 18.17. Invitae Corporation
  • 18.18. Labcorp Holdings Inc.
  • 18.19. Myriad Genetics, Inc.
  • 18.20. Natera, Inc.
  • 18.21. QIAGEN N.V.
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. Siemens Healthineers AG
  • 18.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREDICTIVE GENETICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREDICTIVE GENETICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPRESSION MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY EXPANDED CARRIER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SINGLE GENE CARRIER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CYP TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DRUG METABOLISM TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NON INVASIVE PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR RISK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEURODEGENERATIVE RISK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GENETIC COUNSELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NGS SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NGS SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NGS SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PCR SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PCR SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PCR SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TESTING SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TESTING SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TESTING SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HEART DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 318. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 319. ASEAN PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-203